Hemab Therapeutics Holdings, Inc. (COAG)

Hemab Therapeutics Holdings, Inc. is trading at $53.97, up 0.71% on the session. The 50 day average sits at $37.70 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 68.3, which reads as strong, and MACD is bullish crossover. Volume is below average.

The nearest support is around $43.05 with resistance near $55.42, so that band frames the current range. Average daily movement is roughly $4.11, or about 7.6% of the share price, which is what any stop placement has to allow for. The overall health score of 66 out of 100 combines a trend score of 75, momentum of 88 and a risk score of 22.

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.